Loading...
By Amy Orciari Herman
Edited by David G. Fairchild, MD, MPH, and Lorenzo Di Francesco, MD, FACP, FHM
For patients with uncomplicated cellulitis, adding trimethoprim-sulfamethoxazole (TMP/SMX) to cephalexin may offer no benefit beyond cephalexin alone, a JAMA study finds.
Some 500 patients older than 12 years seen in the emergency department for cellulitis without an abscess (based on soft tissue ultrasound), purulent drainage, or wound were randomized to receive, for 7 days, either cephalexin (500 mg 4 times daily) plus TMP/SMX (320 mg/1600 mg twice daily), or cephalexin plus placebo.
In the primary, per-protocol analysis, the proportion of patients with clinical cure at 14–21 days after enrollment didn't differ significantly between the groups (roughly 85%). In the modified intention-to-treat analysis, however, the clinical cure rate was higher with TMP-SMX plus cephalexin (76% vs. 69%), although the difference still didn't reach statistical significance. Many treatment failures were found to have an abscess.
Editorialists say the findings "indicate that most patients presenting with nonpurulent cellulitis without abscess can be safely treated without the addition of antimicrobials directed against MRSA." They add that the results of the intention-to-treat analysis "were likely skewed by a relatively large number of patients who did not complete the recommended course of therapy."
Comment
LINK(S):
JAMA article (Free abstract)
JAMA editorial (Subscription required)
Background: NEJM Journal Watch Dermatology coverage of guidelines for managing skin and soft tissue infections (Free)
Background: NEJM Journal Watch Infectious Diseases coverage of TMP/SMX vs. clindamycin for uncomplicated skin infections (Free)